RichardE.ChamplinMD

Oncology • Houston, TX

Professor of Medicine, University Texas MD Anderson Cancer Center, Houston

Join to view full profile

Dr. Champlin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Champlin's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1978 - 1980
Los Angeles County-Harbor-UCLA Medical CenterResidency, Internal Medicine, 1975 - 1978
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1975

Certifications & Licensure

CA State Medical License 1976 - Present
FL State Medical License 2021 - Present
WA State Medical License 2023 - 2026
AL State Medical License 2023 - 2025
AZ State Medical License 2023 - 2025
GA State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
OK State Medical License 2020 - 2025
TN State Medical License 2023 - 2025
TX State Medical License 1990 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2006-2014
Top Doctors:SE Texas Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013

Clinical Trials

Bone Marrow Transplantation in Treating Patients With Lymphoma Start of enrollment: 1994 Feb 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Lymphoma Start of enrollment: 1995 Oct 30
Completed
Phase 3
Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia Start of enrollment: 1991 Mar 05
Completed
Phase 2
Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome Start of enrollment: 1999 Dec 01
Completed
Phase 1, Phase 2
CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation Start of enrollment: 2001 May 01
Terminated
Not Applicable
Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases Start of enrollment: 2001 Sep 01
Completed
Phase 2
Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes Start of enrollment: 2001 Jan 31
Withdrawn
Not Applicable
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Start of enrollment: 2006 May 01
Completed
Phase 1
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia Start of enrollment: 2006 Sep 01
Completed
Phase 2
IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome Start of enrollment: 2005 Jun 01
Completed
Phase 3
Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies Start of enrollment: 2007 May 01
Terminated
Phase 1
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients Start of enrollment: 2003 Feb 01
Terminated
Phase 2
Busulfan and Fludarabine in Patients With AML and MDS Start of enrollment: 2003 Oct 01
Completed
Phase 2
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML) Start of enrollment: 2008 Dec 01
Completed
Phase 2
PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic Transplantation Start of enrollment: 2008 Mar 01
Withdrawn
Phase 1
Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) Start of enrollment: 2009 Apr 21
Completed
Phase 3
Selecting a Favorable KIR Donor in Unrelated HCT for AML Start of enrollment: 2011 Jun 01
Completed
Not Applicable
Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG Start of enrollment: 2012 Jan 01
Completed
Phase 2
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Start of enrollment: 2011 Nov 02
Completed
Phase 3
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) Start of enrollment: 2012 Feb 01
Terminated
Phase 2
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies Start of enrollment: 2013 Jun 11
Completed
Phase 1, Phase 2
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene Start of enrollment: 2013 Dec 27
Terminated
Phase 1, Phase 2
Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML Start of enrollment: 2014 Feb 06
Completed
Phase 2
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant Start of enrollment: 2019 Aug 08
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms.
Jayastu Senapati, Sanam Loghavi, Guillermo Garcia-Manero, Guillin Tang, Tapan Kadia
Haematologica. 2024-12-12
1 citations
A Multicenter Analysis of Allogeneic Transplant Outcomes in Adults with Philadelphia-Like B-Cell Acute Lymphoblastic Leukemia in First Complete Remission.
Zaid Abdel Rahman, Tamer Othman, Rima M Saliba, Yenny Alejandra Moreno Vanegas, Razan Mohty
Transplantation and Cellular Therapy. 2024-12-01
Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant.
Curtis Marcoux, Sarah Pasyar, Denái R Milton, Hina N Khan, Mark R Tanner
British Journal of Haematology. 2024-11-28

Journal Articles

Primary Plasma Cell Leukemia: Autologous Stem Cell Transplant in an Era of Novel Induction Drugs
Krina Patel, Rohtesh Mehta, Donna M Weber, Sheeba K Thomas, Nina Shah, Hans C Lee, Elisabet E Manasanch, Muzaffar H Qazilbash, Qaiser Bashir, Simrit Parmar, Robert Z O..., Nature
Pilot Study Using Post-Transplant Cyclophosphamide (PTCy), Tacrolimus and Mycophenolate GVHD Prophylaxis for Older Patients Receiving 10/10 HLA-Matched Unrelated Donor...
Uday R Popat, Amin Alousi, Issa F Khouri, Muzaffar Qazilbash, Richard E Champlin, Partow Kebriaei, Simrit Parmar, Chitra Hosing, Nature
Impact of a Novel Prognostic Model, Hematopoietic Cell Transplant-Composite Risk (HCT-CR), on Allogeneic Transplant Outcomes in Patients with Acute Myeloid Leukemia an...
Uday Popat, Chitra M Hosing, Issa Khouri, Richard Champlin, Simrit Parmar, Partow Kebriaei, Borje S Andersson, Qaiser Bashir, Amin Alousi, Nature

Abstracts/Posters

Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation
Richard E. Champlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Clinical Relevance of MYC/BCL2 and Cell of Origin in Patients with Relapsed Diffuse Large B-Cell Lymphoma Treated with Autologous Stem Cell Transplantation
Richard E. Champlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Post-Transplant Cyclophosphamide (PT-Cy) Based Haploidentical Cell Transplantation (Haplo) Versus Rabbit Anti-Thymocyte Globulin (r-ATG) Based HLA Matched Unrelated Do...
Richard E. Champlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients
Richard E. Champlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Blinatumomab Is Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
Richard E. Champlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)
Richard E. Champlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Allogeneic Cord Blood Regulatory T Cells Can Prevent Graft Vs. Host Disease and Preserve Graft Vs Leukemia Effect: Update on Phase I/II Clinical Trial
Richard E. Champlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation
Richard E. Champlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pt...
Richard E. Champlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Next Generation CRISPR Gene-Edited and Off-the-Shelf Virus-Specific T-Cells for the Immunocompromised Patient
Richard E. Champlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML)
Richard E. Champlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma _ Cohort Study of 369 Patients
Richard E. Champlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
Richard E. Champlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receivi...
Richard E. Champlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Combining CAR Engineering and CIS Checkpoint Deletion in NK Cells for the Treatment of B Cell Hematologic Malignancies
Richard E. Champlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Outcome of Autologous Stem Cell Transplantation in Waldenström's Macroglobulinemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation after Double Cord Blood Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib E...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Older Age As a Prognostic Factor for Overall Survival for Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Manufacture of Clinical-Grade Universal Antigen Presenting Cells (UAPC) for the Ex Vivo Expansion and Activation of Natural Killer (NK) Cells
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Hematopoietic Cell Transplant -Composite Risk (HCT-CR) - a Novel Prognostic Model to Predict Transplant Outcomes
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

Cell Therapy Ascends: New Hope for Combating Mantle Cell LymphomaOctober 20th, 2020
Myelodysplastic Syndrome Survivor: Why I’ve Been Giving My Care Team Sacagawea CoinsJune 18th, 2020
CD19 CAR NK-Cell Therapy Achieves 73% Response Rate in Patients with Leukemia and LymphomaMarch 7th, 2020
Join now to see all

Grant Support

Improving The Outcomes Of Stem Cell TransplantationNational Heart, Lung, And Blood Institute2011
The Therapy Of CMLNational Cancer Institute2010–2011
Novel Strategies For Hematopoietic Transplantation For Chronic Myeloid LeukemiaNational Cancer Institute2010–2011
AdministrationNational Cancer Institute2010–2011
Hematopoietic Transplantation For AMLNational Cancer Institute2001–2011
Blood Marrow Transplant Clinical Trials Research NetworkNational Heart, Lung, And Blood Institute2009–2010
Therapy Of CMLNational Cancer Institute1996–2007
Allogeneic Bone Marrow Transplantation For CMLNational Cancer Institute1996–2002
Allogenic Blood And Marrow Transplant For Acute Myelogenous LeukemiaNational Cancer Institute1996–2001
Bone Marrow TransplantationNational Cancer Institute1989
A Program In Bone Marrow TransplantationNational Cancer Institute1987–1988

Professional Memberships

American Society of Clinical Oncology - ASCO
Member